Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

On The Respiratory Horizon: A Wave Of Biologics For Asthma

Executive Summary

Several antibody drugs are in late-stage development to treat severe asthma and could reach the market in the next two years. But competition for niche subsets of patients will be fierce, and tailoring the right medications to the right patients to justify the higher cost of treatment will require advances in biomarker development.

Advertisement

Related Content

AstraZeneca Hopes To Differentiate Benralizumab On Efficacy, Dosing Convenience
Roche Reviewing Next Steps For Lebrikizumab After Mixed Phase III Data
GSK’s Mepolizumab Panel Review May Hinge On Eosinophil Utility In Patient Selection
Teva Points To Progress In Specialty Despite Headwinds For Copaxone
COPD Market Snapshot: New Products, Limited Differentiation
Roche Believes Biomarker Could Position Antibody For Severe Asthma For Success
In Cephalon, Teva Will Get An Expanded Innovative R&D And Branded Portfolio
Second Time Around: Cephalon Buys Ception Based On Cinquil Data In Asthma

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS055481

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel